Merz licenses TAU Alzheimer's drug

Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

By YONI TEITZ
July 11, 2007 08:47
Merz licenses TAU Alzheimer's drug

pills 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Tel Aviv University has licensed an Alzheimer's treatment it developed to Merz Pharmaceuticals, a German producer of Alzheimer's drugs. Ramot, Tel Aviv University's technology transfer company, raised $8.5 million for research into the treatment in 2003. Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM